Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker

Clinical Cancer Research

Volumn 23, Issue 1, 2017, Pages 116-123

  Pietrasz, Daniel ^a,b,c   Pécuchet, Nicolas ^b   Garlan, Fanny ^b   Didelot, Audrey ^b   Dubreuil, Olivier ^a   Doat, Solène ^a   Imbert Bismut, Francoise ^a   Karoui, Mehdi ^a,c   Vaillant, Jean Christophe ^a,c   Taly, Valérie ^b   Laurent Puig, Pierre ^b   Bachet, Jean Baptiste ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Therapeutic Implications Laboratoire d'Excellence GR Ex   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 4; K RAS PROTEIN; PROTEIN KINASE LKB1; PROTEIN P53; SMAD4 PROTEIN; TUMOR DNA; UNCLASSIFIED DRUG; CIRCULATING TUMOR DNA; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DNA DETERMINATION; DNA SEQUENCE; ERBB4 GENE; EVOLUTION; FEASIBILITY STUDY; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; HUMAN; KRAS GENE; MAJOR CLINICAL STUDY; MALE; MUTATION ALLELIC FREQUENCY; NEXT GENERATION SEQUENCING; NRAS GENE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PICOLITER DROPLET DIGITAL POLYMERASE CHAIN REACTION; PIK3CA GENE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; SEX DIFFERENCE; SMAD4 GENE; STK11 GENE; SURVIVAL TIME; TP53 GENE; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; ADENOCARCINOMA; CANCER GRADING; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR EMBOLISM; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CIRCULATING TUMOR DNA; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 85010211556     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0806     Document Type: Article

References (29)

1. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012;118:2338-66.
2. Bouvier AM, Remontet L, Jougla E, Launoy G, Grosclaude P, Buemi A, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 2004;28:877-81.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
4. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
5. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703.
6. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 2013;13:340-51.
7. Hong SM, Park JY, Hruban RH, Goggins M. Molecular signatures of pancreatic cancer. Arch Pathol Lab Med 2011;135:716-27.
8. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015;518:495-501.
9. di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013;144:1220-9.
10. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003;21:3902-8.
11. Gal S, Fidler C, Lo YM, Taylor M, Han C, Moore J, et al. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 2004;90:1211-5.
12. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
13. Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012;18:1177-85.
14. Spindler KL, Appelt AL, Pallisgaard N, Andersen RF, Brandslund I, Jakobsen A. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int J Cancer 2014;135:2984-91.
15. Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 2015;26:1715-22.
16. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 2015;6:7686.
17. Marchese R, Muleti A, Pasqualetti P, Bucci B, Stigliano A, Brunetti E, et al. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas 2006;32:171-7.
18. Dabritz J, Preston R, Hanfler J, Oettle H. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas 2009;38:534-41.
19. Kinugasa H, Nouso K, Miyahara K, Morimoto Y, Dohi C, Tsutsumi K, et al. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer 2015;121:2271-80.
20. Chen H, Tu H, Meng ZQ, Chen Z, Wang P, Liu LM. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol 2010;36:657-62.
21. Tops BB, Normanno N, Kurth H, Amato E, Mafficini A, Rieber N, et al. Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. BMC Cancer 2015;15:26.
22. Pécuchet N, Rozenholc Y, Zonta E, Pietrasz D, Didelot A, Combe P, et al. Analysis of base-position error rate of next-generation sequencing to detect tumor mutations in circulating DNA. Clin Chem 2016;62:1492-1503.
23. Pekin D, Skhiri Y, Baret JC, Le Corre D, Mazutis L, Salem CB, et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip 2011;11:2156-66.
24. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
25. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013;59:1722-31.
26. Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, et al. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). Eur J Cancer 2014;50:2983-93.
27. Goggins M, Kern SE, Offerhaus JA, Hruban RH. Progress in cancer genetics: lessons from pancreatic cancer. Ann Oncol 1999;10 Suppl 4:4-8.
28. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
29. Gall TM, Frampton AE, Krell J, Castellano L, Jiao LR. Circulating molecular markers in pancreatic cancer: ready for clinical use? Future Oncol 2013;9:141-4.